BioSpace News Archive

Despite yesterday’s announcement by 9 Meters Biopharma that larazotide acetate drug trials had been discontinued, Beyond Celiac remains resolute in driving research to find treatment and a cure for celiac disease by 2030.

In a presentation titled “Reaching the goal with higher speed and confidence”, CEO Dr Werner Lanthaler and CFO Enno Spillner presented Evotec SE’s current strategic, scientific and technological developments, highlights of the 2021 business year and the commitment to sustainability/ESG.

Data Bridge Market Research latest research report, titled “Biopharmaceuticals Market ” offers a detailed analysis of the market drivers, size, share, demand, segmentation, growth opportunities, trends, and competitive landscape to understand the current and future market scenarios.

MicroPort Orthopedics, a global leader in orthopedic devices and technologies, today announces that it will be hosting its first annual Global Medial-Pivot Symposium in Chicago from October 13-15, 2022.

Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “Company” or “Small Pharma”), a biotechnology company focused on short-acting psychedelic-assisted therapies for mental health conditions, announces that Peter Rands, Chief Executive Officer, and Dr. Carol Routledge, Chief Medical and Scientific Officer, will participate in a fireside chat at the H. C. Wainwright 1st Annual Mental Health Conference.

CytoDyn Inc. announced today that Tanya Urbach, Board Chair will host an investment community webcast to provide a quarterly Company update on Thursday, June 30, 2022.

Athenex, Inc., (NASDAQ: ATNX), today announced the signing of a definitive agreement for the sale of revenues from U.S. and European royalty and milestone interests in Klisyri® (tirbanibulin) to Sagard Healthcare Partners and funds managed by Oaktree Capital Management, L.P. (“Oaktree”) for $85 million.

Global Life Sciences Industry Executive Transitions from Interim CEO Role to Full-Time Leadership Position to Lead Commercialization of Disruptive Diagnostic Technology.

Antisense Therapeutics Limited announced the results from a first study of antisense to CD49d in a limb girdle muscular dystrophy R2 mouse model.

Elucid, a company developing a novel, non-invasive medical software to comprehensively characterize cardiovascular disease, announced the closing of a $27 Million Series B financing round.